Halozyme Therapeutics Inc (HALO)

Return on equity (ROE)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	281,594	202,129	402,710	129,085	-72,240
Total stockholders’ equity	US$ in thousands	83,808	169,798	196,953	151,047	91,765
ROE		336.00%	119.04%	204.47%	85.46%	-78.72%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $281,594K ÷ $83,808K
= 336.00%

Halozyme Therapeutics Inc.'s return on equity (ROE) has shown significant fluctuations over the past five years. In 2023, the ROE surged to an impressive 336.00%, marking a substantial increase compared to the previous years. This significant rise indicates that the company generated substantial profit relative to its shareholders' equity during that period.

In 2022, the ROE was 119.04%, showing a decrease from the previous year but still a strong performance in generating profits with the shareholders' equity. The company's ROE peaked in 2021 at 204.47%, showcasing another year of robust profitability relative to shareholders' equity.

In 2020, the ROE stood at 85.46%, signaling a lower return compared to the prior year, but still a positive indication of profitability. The performance in 2019 was notably negative, with an ROE of -78.72%, implying that the company incurred a loss relative to the shareholders' equity during that year.

Overall, the fluctuating ROE of Halozyme Therapeutics Inc. indicates varying levels of profitability and efficiency in generating returns for its shareholders over the analyzed period. Investors and stakeholders may consider the trend in ROE as a key factor when assessing the company's financial performance and growth prospects.